Dolby Family Ventures

Paradromics, Inc. is focused on developing brain-machine interfaces that facilitate data transmission between the brain and machines, primarily targeting the treatment of neurodegenerative diseases. The company creates implantable systems capable of decoding complex neural recordings into data streams, which can be utilized by various neural prostheses. Its technology emphasizes high-volume, bidirectional data streaming, allowing patients with neurological disorders to reconnect with their environment and compensate for lost biological connectivity. Founded in 2015 and headquartered in Austin, Texas, Paradromics also offers applications to support its product suite, aiming to enhance the quality of life for individuals with disabilities.

Genemod Corporation, based in Seattle, Washington, specializes in designing and developing inventory management software specifically for life scientists. Established in 2018, the company provides a unified platform that integrates scientific and management tools, enabling effective collaboration and streamlined operations in research laboratories. Its offerings include project management software, sequence editing software, and an intuitive dashboard, all aimed at enhancing workflow efficiency. By utilizing advanced data processing algorithms, Genemod's platform supports life scientists in managing the various tools and tasks necessary for their research, ensuring a user-friendly and secure experience.

Mojo Vision is a company based in Saratoga, California, that specializes in augmented reality products and platforms. Founded in 2015, it has developed a smart contact lens featuring a built-in display that provides timely information without disrupting the user's focus. This innovative technology enables users to receive immediate and relevant information, facilitating hands-free communication and interaction. By minimizing the distractions associated with traditional mobile devices, Mojo Vision aims to enhance connectivity and accessibility for users in various environments.

Cerevance LLC is engaged in the development of therapeutics targeting specific proteins expressed selectively in brain cell types affected by neurological diseases. The company utilizes its proprietary NETSseq platform to profile distinct brain cell types, such as neurons and glial cells, in mature human brain tissue. This technology reveals transcriptional and epigenetic differences, facilitating the early detection and treatment of serious neurological and psychiatric disorders, including Alzheimer’s and Parkinson’s diseases. Founded in 2016, Cerevance is headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom. The company's focus is on advancing new medicines for central nervous system diseases by addressing the underlying mechanisms of neurodegeneration and related conditions.

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

OKAPI:Orbits is a SaaS startup dedicated to making space travel more sustainable through Collision Avoidance Software for satellites.

Developer of semi-autonomous satellite systems designed to deliver real-time insights from space-based systems directly to users. The company provides technical expertise in the areas of computer vision and machine learning in embedded systems for several different market segments including space, IoT, Industry, and biomedical, enabling clients to get maximum output from satellites.

DigiLens Inc. is a developer and manufacturer of optical platform and photopolymer technology solutions specializing in waveguide displays for extended reality (XR) applications. The company offers a range of products, including the Crystal30 and Crystal50 lenses, which enable original equipment manufacturers (OEMs) to create customizable XR devices for both enterprise and consumer markets. DigiLens also provides innovative solutions like the DigiLens AutoHUD, which enhances the field of view and reduces component size in heads-up displays, and CrystalClear, an augmented reality heads-up display. In addition to display technologies, DigiLens supplies light engines and hardware development kits, such as Insight30, which assist users in evaluating and developing wearable devices. Founded in 1997 and based in Sunnyvale, California, DigiLens has positioned itself as a leader in holographic waveguide technology, enabling various industries, including automotive, enterprise, consumer, avionics, and military, to leverage XR capabilities.

Diamond Age automates the construction of single-family homes and makes the American Dream affordable. It is based in Pleasanton, CA, USA.

Mojo Vision is a company based in Saratoga, California, that specializes in augmented reality products and platforms. Founded in 2015, it has developed a smart contact lens featuring a built-in display that provides timely information without disrupting the user's focus. This innovative technology enables users to receive immediate and relevant information, facilitating hands-free communication and interaction. By minimizing the distractions associated with traditional mobile devices, Mojo Vision aims to enhance connectivity and accessibility for users in various environments.

Ursa Major Technologies, Inc. specializes in manufacturing propulsion solutions for the microsatellite and nanosatellite launch market. Founded in 2015 and headquartered in Berthoud, Colorado, the company develops advanced engines, including the Ursa Major Hadley and the Ursa Major Ripley. These propulsion systems are primarily composed of materials that are over 80% additively manufactured, utilizing innovative manufacturing techniques to optimize part creation. Ursa Major's propulsion engines operate on liquid oxygen and kerosene, providing aerospace clients with high-performance, cost-effective, and reliable solutions for launch and hypersonic applications.

Sepion is an advanced membrane company offering a platform suite of highly-tunable nanoscale membranes for multiple industrial markets.

Cala Health, Inc. is a bioelectronic medicine company focused on developing innovative therapies for chronic diseases. Based in Burlingame, California, the company specializes in wearable neuromodulation devices that utilize advancements in neuroscience and technology to provide individualized peripheral nerve stimulation. Its flagship product, Cala Trio, is a non-invasive therapy designed to offer relief from hand tremors in adults with essential tremor, a condition affecting millions. In addition to its current offerings, Cala Health is actively developing new therapeutic solutions in the fields of neurology, cardiology, and psychiatry, aiming to enhance the standard of care for patients with chronic conditions. Founded in 2013, the company has garnered support from prominent investors in both the healthcare and technology sectors.

DigiLens Inc. is a developer and manufacturer of optical platform and photopolymer technology solutions specializing in waveguide displays for extended reality (XR) applications. The company offers a range of products, including the Crystal30 and Crystal50 lenses, which enable original equipment manufacturers (OEMs) to create customizable XR devices for both enterprise and consumer markets. DigiLens also provides innovative solutions like the DigiLens AutoHUD, which enhances the field of view and reduces component size in heads-up displays, and CrystalClear, an augmented reality heads-up display. In addition to display technologies, DigiLens supplies light engines and hardware development kits, such as Insight30, which assist users in evaluating and developing wearable devices. Founded in 1997 and based in Sunnyvale, California, DigiLens has positioned itself as a leader in holographic waveguide technology, enabling various industries, including automotive, enterprise, consumer, avionics, and military, to leverage XR capabilities.

TripleBlind, Inc. is a Kansas City-based company established in 2019 that provides a platform designed for secure collaboration involving sensitive data and algorithms. The company offers digital privacy as a service, equipping organizations with a suite of tools that allows them to share and utilize highly sensitive information in an encrypted environment. This innovative approach ensures that privacy is maintained, enabling entities to work together without the risk of compromising their data security.

H2U Technologies is a clean-energy company focused on advancing the production of green hydrogen through the development of innovative electrocatalyst technologies. The company has created a proprietary electrocatalyst discovery process that utilizes an ultrahigh throughput AI and data-driven approach. This process enables the preparation, characterization, and quantification of millions of catalyst compositions each month, leveraging big data analysis to refine and guide further research. In addition to its electrocatalyst technology, H2U Technologies has developed an iridium-free proton exchange membrane aimed at reducing the costs associated with green hydrogen production. By combining these advancements, the company provides clients with low-cost, long-duration energy storage solutions, promoting the adoption of clean energy alternatives.

Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.

Diamond Age automates the construction of single-family homes and makes the American Dream affordable. It is based in Pleasanton, CA, USA.

H2U Technologies is a clean-energy company focused on advancing the production of green hydrogen through the development of innovative electrocatalyst technologies. The company has created a proprietary electrocatalyst discovery process that utilizes an ultrahigh throughput AI and data-driven approach. This process enables the preparation, characterization, and quantification of millions of catalyst compositions each month, leveraging big data analysis to refine and guide further research. In addition to its electrocatalyst technology, H2U Technologies has developed an iridium-free proton exchange membrane aimed at reducing the costs associated with green hydrogen production. By combining these advancements, the company provides clients with low-cost, long-duration energy storage solutions, promoting the adoption of clean energy alternatives.

Paradromics, Inc. is focused on developing brain-machine interfaces that facilitate data transmission between the brain and machines, primarily targeting the treatment of neurodegenerative diseases. The company creates implantable systems capable of decoding complex neural recordings into data streams, which can be utilized by various neural prostheses. Its technology emphasizes high-volume, bidirectional data streaming, allowing patients with neurological disorders to reconnect with their environment and compensate for lost biological connectivity. Founded in 2015 and headquartered in Austin, Texas, Paradromics also offers applications to support its product suite, aiming to enhance the quality of life for individuals with disabilities.

Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.

TripleBlind, Inc. is a Kansas City-based company established in 2019 that provides a platform designed for secure collaboration involving sensitive data and algorithms. The company offers digital privacy as a service, equipping organizations with a suite of tools that allows them to share and utilize highly sensitive information in an encrypted environment. This innovative approach ensures that privacy is maintained, enabling entities to work together without the risk of compromising their data security.

Roviero is focused on transforming the electric vehicle charging infrastructure while also developing advanced technology for edge computing. The company specializes in native graph processors that provide efficient artificial intelligence solutions. These processors are low-power, digital, fully programmable neural network engines designed to simplify the compiler complexity. This innovation enables product developers to create a range of edge computing devices, including cameras, Internet of Things devices, mobile phones, and intelligent computers. Roviero aims to enhance the capabilities of these devices through its cutting-edge technology, positioning itself as a key player in both the electric vehicle and edge computing sectors.

Diamond Age automates the construction of single-family homes and makes the American Dream affordable. It is based in Pleasanton, CA, USA.

CytoVale, Inc. is a biotechnology company based in San Francisco, California, that specializes in developing biomarkers derived from the mechanical properties of individual cells, a field known as mechanomics. Utilizing advanced microfluidics technology, CytoVale routes and physically probes these cells to measure multiple biomarkers simultaneously. The company's innovative approach aims to transform diagnostics, particularly in the early detection of sepsis, enhancing patient outcomes while also reducing treatment costs. Established in 2012, CytoVale combines the principles of cell mechanics with machine learning to create reliable biophysical markers that can significantly improve clinical decision-making.

Sea Machines Robotics, Inc. is an autonomous technology company based in Boston, Massachusetts, specializing in the development of autonomous control and navigation systems for the commercial marine and boating industries. Founded in 2014, the company creates advanced control systems for vessels, including unmanned surface vessels, aimed at enhancing operational safety and productivity on the water. Its product offerings include the SM300, which allows for remote command of vessels; the SM200, which supports collaborative vessel operations; the SM400, an AI-powered situational awareness system for container ships; and the RC NXT, which enables wireless control of existing or new marine vessels. Additionally, Sea Machines provides the DP-NXT system, which upgrades traditional vessels for reduced or zero crew operations. The company also delivers solutions for unmanned applications such as bathymetric survey vessels, subsea asset inspections, and acoustic monitoring, thereby improving efficiency and safety in challenging marine environments.

Authentic Vision GmbH, founded in 2012 and headquartered in Salzburg, Austria, specializes in anti-counterfeiting and authentication technologies designed to safeguard organizations' investments in product innovation and brand reputation. The company offers a unique solution featuring a patented label technology that integrates the advantages of QR codes with the security features of holograms. This is complemented by the CheckifReal application, a visual recognition tool that helps users distinguish between Authentic Vision labels and counterfeit replicas. Additionally, Authentic Vision provides services in customer communication, client label management, business intelligence, and information collection. The company's commitment to innovation is underscored by its collaboration with universities and leading security printing firms to advance brand protection and customer communication solutions.

Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.

NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain. Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies for individuals with chronic neurological diseases. The company operates in the burgeoning field of bioelectronics, merging principles of biology and electronics to create innovative therapeutic solutions. The name "Salvia," derived from the Latin word for "to stay healthy," reflects the company's commitment to enhancing health and well-being. Salvia aims to deliver accessible bioelectronic treatments that address severe neurological disorders. The team comprises experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, ensuring a strong foundation for the development of their cutting-edge technologies.

NativeWaves specializes in streaming solutions for various sectors, including broadcasting, e-Sports, events, and cinema. Founded in 2016 and based in Himmelreich, Salzburg, Austria, the company focuses on providing synchronized and personalized content delivery without disrupting existing workflows for broadcasters. Its technology allows users to access multiple camera views on mobile devices, enabling them to choose their preferred perspective during live events. Additionally, NativeWaves offers a unique feature that translates movies, sports events, and videos into any language, ensuring seamless playback without buffering or synchronization issues. The platform also provides real-time statistics and insights on an alternate screen, enhancing the viewing experience by allowing users to engage with their favorite content in their desired style.

Atomwise, Inc. specializes in deep learning artificial intelligence technology aimed at small molecule drug discovery. The company leverages its proprietary AI platform, AtomNet, which contains over 16 billion molecules for virtual screening, to enhance the speed and accuracy of drug discovery processes. This technology employs a statistical approach to predict the binding of small molecules to proteins, aiding in drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise collaborates on numerous projects each year with major pharmaceutical and agrochemical companies, as well as over 200 universities and hospitals across 40 countries. Founded in 2012 and based in San Francisco, Atomwise was previously known as Chematria, Inc. before rebranding in 2015.

Atomwise, Inc. specializes in deep learning artificial intelligence technology aimed at small molecule drug discovery. The company leverages its proprietary AI platform, AtomNet, which contains over 16 billion molecules for virtual screening, to enhance the speed and accuracy of drug discovery processes. This technology employs a statistical approach to predict the binding of small molecules to proteins, aiding in drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise collaborates on numerous projects each year with major pharmaceutical and agrochemical companies, as well as over 200 universities and hospitals across 40 countries. Founded in 2012 and based in San Francisco, Atomwise was previously known as Chematria, Inc. before rebranding in 2015.

QurAlis Corporation is a biotechnology company focused on discovering and developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurological diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis aims to address the genetic underpinnings of ALS, leveraging its proprietary platforms and biomarkers to create targeted treatments. The company's pipeline includes innovative therapies designed to restore dysfunctional cellular processes, treat overactive neurons, and eliminate toxic proteins associated with the disease. By concentrating on genetically validated targets, QurAlis seeks to advance antisense oligonucleotides and small molecule programs that can effectively manage various subtypes of ALS, ultimately working to halt disease progression and improve patient outcomes. QurAlis operates as a subsidiary of Q-State Biosciences, Inc.

Cerevance LLC is engaged in the development of therapeutics targeting specific proteins expressed selectively in brain cell types affected by neurological diseases. The company utilizes its proprietary NETSseq platform to profile distinct brain cell types, such as neurons and glial cells, in mature human brain tissue. This technology reveals transcriptional and epigenetic differences, facilitating the early detection and treatment of serious neurological and psychiatric disorders, including Alzheimer’s and Parkinson’s diseases. Founded in 2016, Cerevance is headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom. The company's focus is on advancing new medicines for central nervous system diseases by addressing the underlying mechanisms of neurodegeneration and related conditions.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Atmosic Technologies, Inc. is a fabless semiconductor company based in Campbell, California, founded in 2016. The company specializes in designing ultra-low power wireless technologies aimed at significantly reducing the dependency of Internet of Things (IoT) devices on batteries. Its innovative products enable a range of connected wireless devices, including wearables, asset trackers, and beacons, to achieve extended battery life or operate without batteries altogether. This advancement not only enhances device performance but also lowers the costs and efforts associated with the deployment and maintenance of IoT systems across various sectors, including personal, home, automotive, healthcare, industrial, enterprise, and smart cities.

GenomSys SA is a Swiss company focused on developing tools and applications for processing and sharing DNA data, founded in 2016 and based in Lausanne. The company offers a secure platform that allows individuals to store their DNA information on personal devices and share it with healthcare practitioners for various purposes, including diagnostics, pharmacogenomics, personalized treatments, and dietary recommendations. GenomSys employs a team of engineers with extensive experience in high-end technology domains, such as digital signal processing and information security. Their expertise covers a wide range of development areas, from embedded software for low-power devices to real-time programming in safety-critical environments. The company also emphasizes compliance with ISO standards and provides a marketplace for vertical genomic analysis applications, promoting international open standards for genomic data to enhance the quality of genomic analyses available to users.

Strateos operates a robotic cloud laboratory that automates chemistry, biology, and tissue analysis to enhance drug discovery processes. By integrating advanced robotics, control systems, and sophisticated imaging and analytics software, Strateos allows pharmaceutical companies to discover new drug candidates more efficiently. The company emerged from a merger between Transcriptic, known for its pioneering robotic cloud laboratory platform, and 3Scan, which specialized in using automation and machine learning to analyze tissue samples. This combination enables Strateos to provide a comprehensive suite of technologies designed to streamline the drug discovery and early development phases. By transforming life science methodologies into data-driven processes, Strateos aims to create a more efficient and cost-effective approach to scientific research, positioning itself as a valuable partner to biotechnology firms seeking to innovate in the field.

Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.

Lightform, Inc. is a San Francisco-based company founded in 2014 that specializes in computer vision and hardware for projected augmented reality. The company develops a desktop application that enables users to create animated content for various scenes, as well as update and control projectors wirelessly using laptops or smartphones. Lightform's technology allows for the integration of its system with any projector, facilitating the creation of immersive experiences through light. In addition to its core offerings, the company provides 3D scanning options and cloud services to enhance the user experience and support its products.

NativeWaves specializes in streaming solutions for various sectors, including broadcasting, e-Sports, events, and cinema. Founded in 2016 and based in Himmelreich, Salzburg, Austria, the company focuses on providing synchronized and personalized content delivery without disrupting existing workflows for broadcasters. Its technology allows users to access multiple camera views on mobile devices, enabling them to choose their preferred perspective during live events. Additionally, NativeWaves offers a unique feature that translates movies, sports events, and videos into any language, ensuring seamless playback without buffering or synchronization issues. The platform also provides real-time statistics and insights on an alternate screen, enhancing the viewing experience by allowing users to engage with their favorite content in their desired style.

Kuprion Inc. is a manufacturer and licensor of nano copper inks and pastes, primarily used in printable electronics and integrated circuit chips. Founded in 2016 and based in Palo Alto, California, the company specializes in its NSA-16 nano copper solder adhesive, which is designed for applications across various sectors, including aerospace, automotive, consumer electronics, and healthcare. Kuprion's technology, which emerged from research at Lockheed Martin, offers superior electrical and thermal conductivity compared to traditional solder, making it suitable for high-performance and high-reliability applications in smaller and more powerful electronic devices. The company also provides assembly, packaging, and consulting services, and has secured numerous patents and significant interest from major commercial clients. With manufacturing capabilities in San Jose, California, Kuprion aims to revolutionize the market for advanced electronics by offering a reliable, RoHS-compliant alternative to conventional materials.

Phylagen, Inc. is a data analytics company based in San Francisco, California, that focuses on microbiome data solutions. Founded in 2014, the company employs DNA sequencing and machine learning to analyze complex genetic signatures found within the environmental microbiome. By transforming this extensive and largely unexplored dataset into actionable insights, Phylagen aims to support decision-making for businesses across various industries. Through its innovative approach, Phylagen harnesses the potential of microbial data to provide valuable analytics that can enhance operations and strategies for its clients.

Ultraleap is a leader in mid-air haptic technology and 3D hand tracking, specializing in creating tactile feedback through ultrasound. This innovative technology allows users to experience touch sensations in mid-air, enabling interactions with virtual objects, touchless buttons, and mid-air gestures without the need for physical contact. The company offers a range of products, including the Evaluation Kit, which features ultrasonic transducers and a software development kit for programming haptic sensations, and the TOUCH Development Kit, designed for creating tactile feedback in free space. Ultraleap’s technology finds applications in various sectors, including virtual reality, gaming, automotive, medical, and advertising. Established in 2013, the company operates from its headquarters in Bristol, United Kingdom, and maintains an additional office in Mountain View, California.

Mojo Vision is a company based in Saratoga, California, that specializes in augmented reality products and platforms. Founded in 2015, it has developed a smart contact lens featuring a built-in display that provides timely information without disrupting the user's focus. This innovative technology enables users to receive immediate and relevant information, facilitating hands-free communication and interaction. By minimizing the distractions associated with traditional mobile devices, Mojo Vision aims to enhance connectivity and accessibility for users in various environments.

System1 Biosciences, Inc., founded in 2017 and headquartered in San Francisco, California, is a neurotherapeutics company focused on drug discovery for complex neurological and psychiatric diseases such as epilepsy, autism, and schizophrenia. By utilizing phenotypic screening, the company aims to overcome the limitations of existing discovery techniques in these challenging areas. System1 integrates cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to achieve detailed characterizations of diseases, referred to as "deep phenotypes." These insights are employed to identify novel therapeutic targets and develop effective drug treatments.

Vium, Inc. is a biotechnology company focused on transforming preclinical research and enhancing animal welfare through the development of digital biomarkers. Founded in 2013 and headquartered in San Mateo, California, Vium employs advanced technologies such as artificial intelligence, machine learning, and sensor technology to create its Digital Vivarium and Vium Cloud platforms. These platforms enable non-invasive collection of physiological metrics and behaviors, yielding more sensitive and accurate data for researchers. Vium's offerings cater to a diverse clientele, including biotechnology, pharmaceutical, and computational drug discovery firms, as well as academic institutions and therapeutic labs. The company is fully accredited by AAALAC International and has received commendations for its commitment to humane animal research, adhering to the principles of the 3 Rs—Replacement, Reduction, and Refinement. By providing critical insights into disease progression, Vium assists researchers in making informed decisions about which compounds should advance to clinical trials, thereby accelerating the drug discovery and development pipeline.

Paradromics, Inc. is focused on developing brain-machine interfaces that facilitate data transmission between the brain and machines, primarily targeting the treatment of neurodegenerative diseases. The company creates implantable systems capable of decoding complex neural recordings into data streams, which can be utilized by various neural prostheses. Its technology emphasizes high-volume, bidirectional data streaming, allowing patients with neurological disorders to reconnect with their environment and compensate for lost biological connectivity. Founded in 2015 and headquartered in Austin, Texas, Paradromics also offers applications to support its product suite, aiming to enhance the quality of life for individuals with disabilities.

Zebra Medical Vision Ltd. is an Israeli company founded in 2014 that specializes in developing an imaging analytics platform aimed at enhancing healthcare delivery. The platform provides a comprehensive suite of imaging research solutions for clinicians, advanced machine learning and computer vision diagnostic algorithms for developers, and risk management tools for healthcare providers. By offering access to a vast repository of anonymized clinical records, Zebra Medical Vision supports researchers in accelerating the development of decision support tools and improving diagnostic accuracy. The company collaborates with various partners, including USARAD Holdings and TELUS Ventures, to leverage its network of over 1,100 hospitals and healthcare providers. This collaboration fosters innovation and enhances patient care through the application of advanced analytics and automated clinical insights, positioning Zebra Medical Vision as a leader in the integration of AI and machine learning in medical imaging.

Cortexyme, Inc. is a clinical stage biopharmaceutical company based in South San Francisco, California, focused on developing therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's lead drug candidate, COR388, is an orally administered small molecule designed to inhibit gingipain, which is linked to neurodegeneration. Currently in Phase II/III clinical trials, COR388 targets patients with mild to moderate Alzheimer's disease. Cortexyme's research is grounded in a novel theory linking a specific, undisclosed pathogen to the progression of neurodegenerative conditions, a hypothesis supported by various animal model studies. The company was founded in 2012 and continues to advance its therapeutic candidates through preclinical and clinical development phases.

Phase Four LLC manufactures satellite propulsion systems. It also provides CubeSats ambipolar thruster, an electrodeless permanent magnet helicon thruster; and Maxwell, a turn key plasma propulsion solution for small satellites. The company’s products are used in commercial, civil, and scientific space missions. The company was incorporated in 2015 and is based in Pasadena, California.

Atomwise, Inc. specializes in deep learning artificial intelligence technology aimed at small molecule drug discovery. The company leverages its proprietary AI platform, AtomNet, which contains over 16 billion molecules for virtual screening, to enhance the speed and accuracy of drug discovery processes. This technology employs a statistical approach to predict the binding of small molecules to proteins, aiding in drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise collaborates on numerous projects each year with major pharmaceutical and agrochemical companies, as well as over 200 universities and hospitals across 40 countries. Founded in 2012 and based in San Francisco, Atomwise was previously known as Chematria, Inc. before rebranding in 2015.

Tiaki Therapeutics, Inc. is focused on developing microglia-targeted therapeutics aimed at treating dementias. Founded in 2017 and located in Cambridge, Massachusetts, the company leverages insights from academic research to create a platform for discovering small molecule therapeutics that restore microglial function in the aging brain. Tiaki's innovative approach combines human disease datasets with an authentic ex vivo brain model and bioinformatics analyses to identify novel targets for dementia treatment. This methodology allows for patient-specific insights into dysregulated pathways associated with neuroinflammatory diseases, facilitating the analysis of genomics and transcriptomics for advanced drug development. Tiaki is supported by the Dementia Discovery Fund, a venture capital initiative dedicated to fostering effective, disease-modifying therapies for dementia.

Ursa Major Technologies, Inc. specializes in manufacturing propulsion solutions for the microsatellite and nanosatellite launch market. Founded in 2015 and headquartered in Berthoud, Colorado, the company develops advanced engines, including the Ursa Major Hadley and the Ursa Major Ripley. These propulsion systems are primarily composed of materials that are over 80% additively manufactured, utilizing innovative manufacturing techniques to optimize part creation. Ursa Major's propulsion engines operate on liquid oxygen and kerosene, providing aerospace clients with high-performance, cost-effective, and reliable solutions for launch and hypersonic applications.

Envisagenics, Inc. is a biotechnology company headquartered in Huntington, New York, specializing in the development of RNA therapeutics. Founded in 2013, the company utilizes its proprietary SpliceCore platform to analyze RNA-seq data through advanced artificial intelligence and machine learning algorithms. This cloud-based technology aims to simplify the complexity of biomedical data, enabling researchers to identify splicing errors that contribute to genetic diseases and cancers. By accurately predicting drug targets and biomarkers, Envisagenics helps pharmaceutical companies reduce the time and costs associated with drug development. The platform is designed to accelerate the discovery of innovative therapeutic solutions and has the potential to address over 370 known human diseases caused by splicing errors. Through collaborations with biopharmaceutical partners, Envisagenics seeks to enhance the efficiency of drug-target selection and lead design, ultimately improving the therapeutic landscape for patients.

Lightform, Inc. is a San Francisco-based company founded in 2014 that specializes in computer vision and hardware for projected augmented reality. The company develops a desktop application that enables users to create animated content for various scenes, as well as update and control projectors wirelessly using laptops or smartphones. Lightform's technology allows for the integration of its system with any projector, facilitating the creation of immersive experiences through light. In addition to its core offerings, the company provides 3D scanning options and cloud services to enhance the user experience and support its products.

Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reach and positively impact everyone.

Stellar is an advanced commercial operations system created for private aviation combined with an all-digital distribution network. Stellar is reimagining and revolutionizing the business aviation industry with a suite of integrated, cloud-based applications. Its solution is simple enough for single-aircraft operations, yet comprehensive and robust enough to handle the most complex operations with large fleets and multiple bases. It was founded in 2014 and is headquartered in Burlingame, California.

Chirp Microsystems, Inc. designs, develops, and manufactures low power, ultrasonic three-dimensional sensing solutions for consumer electronics, smart homes, and industrial automation. The company was incorporated in 2013 and is headquartered in Berkeley, California.

Mixed Dimensions Inc. specializes in software solutions for the 3D printing industry, focusing on creating connections between the digital and physical realms. Founded in 2009 and based in San Francisco, the company offers several services, including Makeprintable, a cloud-based solution that optimizes and fixes 3D CAD files, and 3D Collectible, which provides a platform for 3D printing services that integrates various printing technologies. Additionally, Mixed Dimensions developed Gameprint, a platform designed for capturing and sharing gameplay moments in a 3D context. By utilizing advanced technologies in 3D printing and robotics, the company aims to enable the on-demand creation of unique objects, thus facilitating a seamless interaction between virtual experiences and physical products.

Alzeca Biosciences develops novel advanced imaging agents for the early diagnosis of neurodegenerative diseases, including Alzheimer’s Disease. Alzheimer’s affects approximately 5.5M Americans at a cost of over $226 billion in care, and affects over 27 million patients worldwide. Its incidence is projected to quadruple by 2050 with costs exceeding $1 trillion in the US alone, unless a more effective diagnostic and treatment method is achieved.

Tempo Automation Inc. is a San Francisco-based electronics manufacturer specializing in the prototyping and low-volume production of printed circuit board assemblies. Founded in 2013, the company leverages a proprietary automation platform that integrates software, data analytics, and advanced manufacturing techniques to enhance speed, precision, and transparency in the development process. This innovative approach creates a seamless digital connection from design to delivery, allowing hardware developers to accelerate innovation and bring new products to market more efficiently. The company's smart factory is designed to optimize the complexities of electronics manufacturing, providing significant advantages in quality and agility for its clients. Tempo Automation is backed by various investors, including venture capital firms and individual investors, who support its mission to transform electronic product development.

Ultraleap is a leader in mid-air haptic technology and 3D hand tracking, specializing in creating tactile feedback through ultrasound. This innovative technology allows users to experience touch sensations in mid-air, enabling interactions with virtual objects, touchless buttons, and mid-air gestures without the need for physical contact. The company offers a range of products, including the Evaluation Kit, which features ultrasonic transducers and a software development kit for programming haptic sensations, and the TOUCH Development Kit, designed for creating tactile feedback in free space. Ultraleap’s technology finds applications in various sectors, including virtual reality, gaming, automotive, medical, and advertising. Established in 2013, the company operates from its headquarters in Bristol, United Kingdom, and maintains an additional office in Mountain View, California.

Cortexyme, Inc. is a clinical stage biopharmaceutical company based in South San Francisco, California, focused on developing therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's lead drug candidate, COR388, is an orally administered small molecule designed to inhibit gingipain, which is linked to neurodegeneration. Currently in Phase II/III clinical trials, COR388 targets patients with mild to moderate Alzheimer's disease. Cortexyme's research is grounded in a novel theory linking a specific, undisclosed pathogen to the progression of neurodegenerative conditions, a hypothesis supported by various animal model studies. The company was founded in 2012 and continues to advance its therapeutic candidates through preclinical and clinical development phases.

Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reach and positively impact everyone.

Echo is a provider of am automated microscope intended for biological research and pathologies. The company's product provides features like inverted images, cell counting, phase contrast, brightfield and fluorescence, enabling customers to have accurate images at a lower cost.

DigiLens Inc. is a developer and manufacturer of optical platform and photopolymer technology solutions specializing in waveguide displays for extended reality (XR) applications. The company offers a range of products, including the Crystal30 and Crystal50 lenses, which enable original equipment manufacturers (OEMs) to create customizable XR devices for both enterprise and consumer markets. DigiLens also provides innovative solutions like the DigiLens AutoHUD, which enhances the field of view and reduces component size in heads-up displays, and CrystalClear, an augmented reality heads-up display. In addition to display technologies, DigiLens supplies light engines and hardware development kits, such as Insight30, which assist users in evaluating and developing wearable devices. Founded in 1997 and based in Sunnyvale, California, DigiLens has positioned itself as a leader in holographic waveguide technology, enabling various industries, including automotive, enterprise, consumer, avionics, and military, to leverage XR capabilities.

Tetra Therapeutics is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Fragile X syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders.

Podium Data, Inc. develops data management software solutions aimed at enhancing how businesses manage and utilize their data. Founded in 2014 and based in Lowell, Massachusetts, the company offers a platform that facilitates source parsing, conversion, validation, data profiling, metadata management, integration, encryption, and transformation. This platform is designed to transform the traditional data supply chain into a self-service marketplace, allowing clients to easily access and understand their enterprise data, regardless of its location. By leveraging big data technologies, Podium Data accelerates the time it takes for organizations to derive insights and make data-driven decisions, ultimately delivering immediate business impact and enabling analytics-ready data for users across various business functions. As of July 2018, Podium Data operates as a subsidiary of Qlik Technologies, Inc.

3Scan, Inc. specializes in developing advanced microscopy tools and software for automated tissue sectioning and imaging, primarily aimed at enhancing large-scale sample analysis and 3D visualizations. Founded in 2010 and based in San Francisco, California, the company focuses on addressing diseases that manifest at the tissue level, including cancer, heart disease, and neurodegenerative disorders. By integrating automation, machine learning, and computer vision, 3Scan's technology enables researchers and medical professionals to achieve greater throughput, improved quantification, and extensive image analysis compared to traditional histopathology methods. This data-driven approach aims to deepen the understanding of tissue biology, facilitating the discovery of new diagnostics and therapeutics. 3Scan was acquired by Transcriptic, Inc. in 2019.

Zebra Medical Vision Ltd. is an Israeli company founded in 2014 that specializes in developing an imaging analytics platform aimed at enhancing healthcare delivery. The platform provides a comprehensive suite of imaging research solutions for clinicians, advanced machine learning and computer vision diagnostic algorithms for developers, and risk management tools for healthcare providers. By offering access to a vast repository of anonymized clinical records, Zebra Medical Vision supports researchers in accelerating the development of decision support tools and improving diagnostic accuracy. The company collaborates with various partners, including USARAD Holdings and TELUS Ventures, to leverage its network of over 1,100 hospitals and healthcare providers. This collaboration fosters innovation and enhances patient care through the application of advanced analytics and automated clinical insights, positioning Zebra Medical Vision as a leader in the integration of AI and machine learning in medical imaging.

Yumanity Therapeutics is a biotechnology company dedicated to transforming drug discovery for neurodegenerative diseases linked to protein misfolding. Founded in December 2014 by protein folding expert Susan Lindquist and biotech leader Tony Coles, Yumanity aims to develop innovative, disease-modifying therapies to address critical unmet medical needs in conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company leverages proprietary platforms to identify potential therapeutic targets and has made progress in advancing a new chemical lead series specifically for Parkinson’s disease, while also exploring additional compounds for Alzheimer's disease and ALS.

Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reach and positively impact everyone.

Modsy is a home design service founded in 2015 and based in San Francisco, California. The company utilizes advanced 3D graphics and computer vision technology to create virtual interior environments, allowing customers to visualize furniture and décor in their own spaces before making purchases. Modsy caters to new homeowners, renters, and remodelers by offering personalized design guidance and plans tailored to individual preferences. Its platform not only showcases inspirational designs but also provides practical recommendations for room layouts and furnishings. Additionally, Modsy features a shoppable marketplace where customers can directly purchase the items featured in their designs, streamlining the home renovation process and reducing uncertainty for users.

Cortexyme, Inc. is a clinical stage biopharmaceutical company based in South San Francisco, California, focused on developing therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's lead drug candidate, COR388, is an orally administered small molecule designed to inhibit gingipain, which is linked to neurodegeneration. Currently in Phase II/III clinical trials, COR388 targets patients with mild to moderate Alzheimer's disease. Cortexyme's research is grounded in a novel theory linking a specific, undisclosed pathogen to the progression of neurodegenerative conditions, a hypothesis supported by various animal model studies. The company was founded in 2012 and continues to advance its therapeutic candidates through preclinical and clinical development phases.

Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, that specializes in developing and selling innovative hearing aids for individuals experiencing hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, addressing common barriers to hearing aid adoption such as cost, accessibility, and social stigma. The company provides online hearing screenings and virtual support, allowing customers to receive assistance without needing in-person visits. Eargo's products are available for purchase online or over the phone, and the company emphasizes personalized consultations with licensed hearing professionals through various communication channels. By offering its solutions at approximately half the cost of traditional hearing aids, Eargo aims to enhance the quality of life for people with hearing impairments.

PharmatrophiX, Inc. is a biopharmaceutical company based in Menlo Park, California, specializing in the development of small molecule drugs aimed at treating neurodegenerative disorders. Founded in 2005 by Stanford researcher Frank Longo, the company utilizes its proprietary PTX technology to create drugs that modulate neurotrophin receptor signaling. This technology includes programs targeting the p75 receptor and Trk ligand, including a modified compound known as LM11A-31, which effectively penetrates the blood-brain barrier. By preventing neurodegenerative signaling and promoting regenerative processes, these drugs offer potential therapeutic benefits for conditions like Alzheimer's disease and other neurodegenerative disorders. PharmatrophiX is committed to providing accessible treatment options for patients suffering from these challenging diseases.

Stellar is an advanced commercial operations system created for private aviation combined with an all-digital distribution network. Stellar is reimagining and revolutionizing the business aviation industry with a suite of integrated, cloud-based applications. Its solution is simple enough for single-aircraft operations, yet comprehensive and robust enough to handle the most complex operations with large fleets and multiple bases. It was founded in 2014 and is headquartered in Burlingame, California.

Eyefluence, Inc. specializes in developing eye-interaction technology that enables control of augmented reality (AR), virtual reality (VR), and mixed reality (MR) head-mounted displays (HMDs) using eye movements. Founded in 2013 and headquartered in Reno, Nevada, the company combines insights from eye biomechanics and the eye-brain connection to create the fastest interface for HMDs. Eyefluence serves manufacturers in the AR, VR, and MR sectors, focusing on enhancing human communication and interaction within these immersive environments. The company is led by experienced entrepreneurs Jim Marggraff and David Stiehr and boasts a multidisciplinary team of experts in various fields, including optics, engineering, and artificial intelligence. Eyefluence holds a robust intellectual property portfolio with over 30 patents, reflecting its commitment to innovation. The company collaborates with emerging startups and established Fortune 100 firms to promote the adoption of smart glasses for various applications across enterprise, industrial, government, and consumer markets. As of October 2016, Eyefluence operates as a subsidiary of Google Inc.

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small molecule therapeutics aimed at addressing neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company is notable for its drug candidate CT1812, an oral brain-penetrant molecule designed to restore cellular processes disrupted by diseases such as Alzheimer’s and dry age-related macular degeneration. Cognition Therapeutics targets the toxic proteins that contribute to cognitive decline, a key factor in various degenerative diseases of the brain. The company employs proprietary assays and medicinal chemistry to create novel, high-quality drug candidates, addressing an unmet need in the treatment of these complex conditions.

AltspaceVR is a virtual reality software company. AltspaceVR is bringing two-dimensional web content into shared virtual spaces, and extending the web to create fully holographic experiences. Through the software users will be able to watch streaming video, play games, and get work done, together and entirely inside of virtual reality. The software is powered by, and fully embraces, the modern open web.

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small molecule therapeutics aimed at addressing neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company is notable for its drug candidate CT1812, an oral brain-penetrant molecule designed to restore cellular processes disrupted by diseases such as Alzheimer’s and dry age-related macular degeneration. Cognition Therapeutics targets the toxic proteins that contribute to cognitive decline, a key factor in various degenerative diseases of the brain. The company employs proprietary assays and medicinal chemistry to create novel, high-quality drug candidates, addressing an unmet need in the treatment of these complex conditions.

ZOZI designs and develops a web-based bookings, payments, and customer management software for tour, activity, and event businesses. It offers introductory flight lessons, vineyard tours and wine tasting by horseback, diving for abalone, ice climbing frozen waterfalls, celebrity and athlete experiences, and various accessible adventures. The company also provides weekend getaways and vacation packages for customers. ZOZI was founded in 2007 and is based in San Francisco, California.

Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, that specializes in developing and selling innovative hearing aids for individuals experiencing hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, addressing common barriers to hearing aid adoption such as cost, accessibility, and social stigma. The company provides online hearing screenings and virtual support, allowing customers to receive assistance without needing in-person visits. Eargo's products are available for purchase online or over the phone, and the company emphasizes personalized consultations with licensed hearing professionals through various communication channels. By offering its solutions at approximately half the cost of traditional hearing aids, Eargo aims to enhance the quality of life for people with hearing impairments.

Vium, Inc. is a biotechnology company focused on transforming preclinical research and enhancing animal welfare through the development of digital biomarkers. Founded in 2013 and headquartered in San Mateo, California, Vium employs advanced technologies such as artificial intelligence, machine learning, and sensor technology to create its Digital Vivarium and Vium Cloud platforms. These platforms enable non-invasive collection of physiological metrics and behaviors, yielding more sensitive and accurate data for researchers. Vium's offerings cater to a diverse clientele, including biotechnology, pharmaceutical, and computational drug discovery firms, as well as academic institutions and therapeutic labs. The company is fully accredited by AAALAC International and has received commendations for its commitment to humane animal research, adhering to the principles of the 3 Rs—Replacement, Reduction, and Refinement. By providing critical insights into disease progression, Vium assists researchers in making informed decisions about which compounds should advance to clinical trials, thereby accelerating the drug discovery and development pipeline.

Mixed Dimensions Inc. specializes in software solutions for the 3D printing industry, focusing on creating connections between the digital and physical realms. Founded in 2009 and based in San Francisco, the company offers several services, including Makeprintable, a cloud-based solution that optimizes and fixes 3D CAD files, and 3D Collectible, which provides a platform for 3D printing services that integrates various printing technologies. Additionally, Mixed Dimensions developed Gameprint, a platform designed for capturing and sharing gameplay moments in a 3D context. By utilizing advanced technologies in 3D printing and robotics, the company aims to enable the on-demand creation of unique objects, thus facilitating a seamless interaction between virtual experiences and physical products.

New Matter, Inc. is a manufacturer of 3D printers aimed at homes, schools, and offices, with a focus on delivering an accessible and integrated 3D printing experience. Founded in 2014 and based in Pasadena, California, the company initially operated under the name IdeaShaper, Inc. Its flagship product, the MOD-t desktop 3D printer, is designed to make 3D printing both affordable and user-friendly, thereby targeting the consumer market with the goal of making this technology widely available. New Matter serves its customers primarily through online channels.

GoBalto is a software platform that develops cloud-based solutions for drug trial sponsors and clinical research organizations. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web. The company was founded in 2008 and headquartered in San Francisco, California.

3Scan, Inc. specializes in developing advanced microscopy tools and software for automated tissue sectioning and imaging, primarily aimed at enhancing large-scale sample analysis and 3D visualizations. Founded in 2010 and based in San Francisco, California, the company focuses on addressing diseases that manifest at the tissue level, including cancer, heart disease, and neurodegenerative disorders. By integrating automation, machine learning, and computer vision, 3Scan's technology enables researchers and medical professionals to achieve greater throughput, improved quantification, and extensive image analysis compared to traditional histopathology methods. This data-driven approach aims to deepen the understanding of tissue biology, facilitating the discovery of new diagnostics and therapeutics. 3Scan was acquired by Transcriptic, Inc. in 2019.

Cortexyme, Inc. is a clinical stage biopharmaceutical company based in South San Francisco, California, focused on developing therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's lead drug candidate, COR388, is an orally administered small molecule designed to inhibit gingipain, which is linked to neurodegeneration. Currently in Phase II/III clinical trials, COR388 targets patients with mild to moderate Alzheimer's disease. Cortexyme's research is grounded in a novel theory linking a specific, undisclosed pathogen to the progression of neurodegenerative conditions, a hypothesis supported by various animal model studies. The company was founded in 2012 and continues to advance its therapeutic candidates through preclinical and clinical development phases.

Keyssa, Inc. specializes in the development and manufacturing of contactless connectors and wireless semiconductors utilizing millimeter-wave technology for data transfer. The company offers a compact system known as Kiss Connectivity, which facilitates simple, secure, and instantaneous data flow between devices without the need for metal connectors, cables, or traditional wireless networks. This innovative solution enables rapid transmission of large amounts of data and video between devices in close proximity while minimizing battery drain. Keyssa's technology relies on extremely high frequency signals and integrates advanced mechanical design, electromagnetics, materials science, and semiconductor technologies. Founded in 2009 and originally known as WaveConnex, Inc., Keyssa is headquartered in Campbell, California, with additional offices in Oregon, China, South Korea, and Taiwan.

Authentic Vision GmbH, founded in 2012 and headquartered in Salzburg, Austria, specializes in anti-counterfeiting and authentication technologies designed to safeguard organizations' investments in product innovation and brand reputation. The company offers a unique solution featuring a patented label technology that integrates the advantages of QR codes with the security features of holograms. This is complemented by the CheckifReal application, a visual recognition tool that helps users distinguish between Authentic Vision labels and counterfeit replicas. Additionally, Authentic Vision provides services in customer communication, client label management, business intelligence, and information collection. The company's commitment to innovation is underscored by its collaboration with universities and leading security printing firms to advance brand protection and customer communication solutions.

Wickr Inc. is a mobile communication application that specializes in providing military-grade encryption for text, images, audio, and video messages. Launched in 2011 and headquartered in San Francisco, California, Wickr offers secure communication channels for both private messaging and collaboration among individuals, small teams, and large enterprises. Its applications, including Wickr Me, facilitate top-secret messaging, enabling users to send and receive encrypted messages without leaving a trace. The platform is designed to protect users’ privacy, as only the recipient can decrypt the messages, and Wickr does not retain decryption keys. With hundreds of thousands of downloads across over 113 countries, Wickr serves a diverse clientele, including reporters, military personnel, celebrities, and everyday users. The company’s protocol for ephemeral messaging employs standard encryption algorithms suitable for mobile devices and can be integrated into other communication platforms, enhancing security and privacy for all users.

CytoVale, Inc. is a biotechnology company based in San Francisco, California, that specializes in developing biomarkers derived from the mechanical properties of individual cells, a field known as mechanomics. Utilizing advanced microfluidics technology, CytoVale routes and physically probes these cells to measure multiple biomarkers simultaneously. The company's innovative approach aims to transform diagnostics, particularly in the early detection of sepsis, enhancing patient outcomes while also reducing treatment costs. Established in 2012, CytoVale combines the principles of cell mechanics with machine learning to create reliable biophysical markers that can significantly improve clinical decision-making.

August Pro, a division of August Home, specializes in providing smart home access solutions tailored for professional installers. Founded in 2012 and headquartered in San Francisco, California, August Home develops advanced smart home products, including the flagship August Smart Lock, which replaces traditional keys with smartphone-controlled access. This technology allows users to create virtual keys for their homes, granting temporary access to house cleaners, dog walkers, delivery services, and others, all managed through a mobile app. The company's products are designed to enhance home security and convenience, enabling homeowners to monitor and control access from anywhere in the world. August Home operates as a subsidiary of ASSA ABLOY AB, further strengthening its position in the smart home market.

BASIS Science, Inc. focuses on enhancing health management through technology. The company has developed a wrist-based health tracker and an online personal dashboard aimed at integrating healthy habits into users' daily routines. This device utilizes advanced sensors to monitor various health metrics, including steps taken, calories burned, sleep quality, and heart rate. Users can set health goals, with the tracker automatically adjusting targets based on their progress, fostering sustainable healthy habits over time. Additionally, BASIS Science offers a mobile mental health application that enables users to book confidential therapy sessions with trained specialists. This platform provides a secure environment for patients to explore coping strategies for their personal challenges, enhancing overall well-being. The company is supported by Norwest Venture Partners and Doll Capital Management.

Littlecast, Inc. is a peer-to-peer e-commerce platform that enables video producers to monetize their content directly to their audiences. Founded in 2013 and headquartered in San Francisco, California, Littlecast allows users to publish, price, and sell a variety of video formats, including stand-up comedy, educational content, documentaries, and music videos, across Facebook, web, and mobile devices. The platform offers features such as content protection, analytics on viewer engagement, and payment processing, ensuring quick payouts for producers. By facilitating direct-to-fan transactions, Littlecast empowers creators to connect with their communities and generate revenue from their work.

Tetra Discovery Partners provides consulting services in drug discovery and development. They partner with Universities to commercialize intellectual property and conduct proprietary research on diseases affecting the central nervous system. Their research focuses on developing new treatments for depression and schizophrenia. Severe forms of depression affect 2–5% of the US population, while mood disorders impact 7% of the world’s population and rank among the top ten causes of disability.

ICON Aircraft, Inc. designs, develops, manufactures, and markets light consumer sport aircraft. The company also operates an online store that sells aircraft gear, such as men’s apparel, women’s apparel, kids’ wear, hats, radio control games, and accessories. It markets its aircraft in the United States and internationally. ICON Aircraft, Inc. was founded in 2004 and is headquartered in Vacaville, California.